{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:01Z","timestamp":1786982341308,"version":"build-2736575974"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12264-020-00525-3","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T07:02:30Z","timestamp":1591945350000},"page":"1213-1224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside"],"prefix":"10.1007","volume":"36","author":[{"given":"Wenli","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"525_CR1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6: 805\u2013815.","journal-title":"Lancet Neurol"},{"key":"525_CR2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","volume":"84","author":"A Jacob","year":"2013","unstructured":"Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013, 84: 922\u2013930.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"525_CR3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008, 4: 202\u2013214.","journal-title":"Nat Clin Pract Neurol"},{"key":"525_CR4","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364: 2106\u20132112.","journal-title":"Lancet"},{"key":"525_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter I. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012, 69: 239.","journal-title":"Arch Neurol"},{"key":"525_CR6","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","volume":"67","author":"J Palace","year":"2010","unstructured":"Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010, 67: 1016\u20131017.","journal-title":"Arch Neurol"},{"key":"525_CR7","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69: 2221\u20132231.","journal-title":"Neurology"},{"key":"525_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202: 473\u2013477.","journal-title":"J Exp Med"},{"key":"525_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015, 85: 177\u2013189.","journal-title":"Neurology"},{"key":"525_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/WCO.0000000000000551","volume":"31","author":"M Bradl","year":"2018","unstructured":"Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol 2018, 31: 325.","journal-title":"Curr Opin Neurol"},{"key":"525_CR11","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 2017, 264: 2088\u20132094.","journal-title":"J Neurol"},{"key":"525_CR12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK. Distinction between MOG antibody- positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014, 82: 474\u2013481.","journal-title":"Neurology"},{"key":"525_CR13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","volume":"24","author":"M Sep\u00falveda","year":"2017","unstructured":"Sep\u00falveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, et al. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler J 2017, 24, 1843-1851.","journal-title":"Mult Scler J"},{"key":"525_CR14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","volume":"59","author":"Y Yan","year":"2016","unstructured":"Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci 2016, 59: 1270\u20131281.","journal-title":"Sci China Life Sci"},{"key":"525_CR15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neurol.2018.02.084","volume":"174","author":"C Alves Do Rego","year":"2018","unstructured":"Alves Do Rego C, Collongues N. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev Neurol 2018, 174: 458\u2013470.","journal-title":"Rev Neurol"},{"key":"525_CR16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","volume":"87","author":"P Durozard","year":"2020","unstructured":"Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin\u20104 antibody diseases. Ann Neurol 2020, 87: 256\u2013266.","journal-title":"Ann Neurol"},{"key":"525_CR17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012, 79: 1273\u20131277.","journal-title":"Neurology"},{"key":"525_CR18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNO.0b013e31823c9b6c","volume":"32","author":"T Kezuka","year":"2012","unstructured":"Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-antibody and anti\u2013MOG antibody in optic neuritis. J Neuroophthalmol 2012, 32: 107\u2013110.","journal-title":"J Neuroophthalmol"},{"key":"525_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","volume":"75","author":"SHM Hamid","year":"2018","unstructured":"Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol 2018, 75: 65\u201371.","journal-title":"JAMA Neurol"},{"key":"525_CR20","first-page":"378","volume":"01","author":"A Ungureanu","year":"2018","unstructured":"Ungureanu A, de Seze J, Ahle G, Sellal F. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Rev Neurol 2018, 01: 378\u2013383.","journal-title":"Rev Neurol"},{"key":"525_CR21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12264-019-00375-8","volume":"35","author":"L Fang","year":"2019","unstructured":"Fang L. Myelin oligodendrocyte glycoprotein-IgG contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG. Neurosci Bull 2019, 35: 853\u2013866.","journal-title":"Neurosci Bull"},{"key":"525_CR22","first-page":"e339","volume":"4","author":"R Bove","year":"2017","unstructured":"Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, et al. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neuroinflammation 2017, 4: e339.","journal-title":"Neuroinflammation"},{"key":"525_CR23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","volume":"79","author":"EP Flanagan","year":"2016","unstructured":"Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum: Aquaporin-4-IgG Seroprevalence. Ann Neurol 2016, 79: 775\u2013783.","journal-title":"Ann Neurol"},{"key":"525_CR24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012, 9: 14.","journal-title":"J Neuroinflammation"},{"key":"525_CR25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","volume":"70","author":"B Banwell","year":"2008","unstructured":"Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008, 70: 344\u2013352.","journal-title":"Neurology"},{"key":"525_CR26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999, 53: 1107\u20131114.","journal-title":"Neurology"},{"key":"525_CR27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"DM Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003, 60: 848\u2013853.","journal-title":"Neurology"},{"key":"525_CR28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130: 1235\u20131243.","journal-title":"Brain"},{"key":"525_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2013.03.003","volume":"260","author":"K Miyazaki","year":"2013","unstructured":"Miyazaki K, Abe Y, Iwanari H, Suzuki Y, Kikuchi T, Ito T, et al. Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. J Neuroimmunol 2013, 260: 107\u2013116.","journal-title":"J Neuroimmunol"},{"key":"525_CR30","doi-asserted-by":"crossref","first-page":"36837","DOI":"10.1074\/jbc.M112.408716","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan PW, Anderson MO, Tradtrantip L, Zhang H, Tan J, Lam C, et al. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. J Biol Chem 2012, 287: 36837\u201336844.","journal-title":"J Biol Chem"},{"key":"525_CR31","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","volume":"26","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Anderson MO, Saadoun S, Phuan PW, Papadopoulos MC, et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 2012, 26: 2197\u20132208.","journal-title":"FASEB J"},{"key":"525_CR32","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","volume":"83","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Asavapanumas N, Verkman AS. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol 2013, 83: 1268\u20131275.","journal-title":"Mol Pharmacol"},{"key":"525_CR33","first-page":"112","volume":"2009","author":"J Leavitt","year":"2009","unstructured":"Leavitt J. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Yearb Neurol Neurosurg 2009, 2009: 112\u2013113.","journal-title":"Yearb Neurol Neurosurg"},{"key":"525_CR34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","volume":"13","author":"K Miyamoto","year":"2009","unstructured":"Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009, 13: 505\u2013508.","journal-title":"Ther Apher Dial"},{"key":"525_CR35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 2014, 10: 493\u2013506.","journal-title":"Nat Rev Neurol"},{"key":"525_CR36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","volume":"9","author":"SH Kim","year":"2013","unstructured":"Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 2013, 9: 36\u201342.","journal-title":"J Clin Neurol"},{"key":"525_CR37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev-pharmtox-010611-134628","volume":"52","author":"K Van Herle","year":"2012","unstructured":"Van Herle K, Behne JM, Van Herle A, Blaschke TF, Smith TJ, Yeaman MR. Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases. Annu Rev Pharmacol Toxicol 2012, 52: 523\u2013547.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"525_CR38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14712598.2013.767329","volume":"13","author":"L Klotz","year":"2013","unstructured":"Klotz L, Wiendl H. Monoclonal antibodies in neuroinflammatory diseases. Expert Opin Biol Ther 2013, 13: 831\u2013846.","journal-title":"Expert Opin Biol Ther"},{"key":"525_CR39","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology 2014, 82: 1302\u20131306.","journal-title":"Neurology"},{"key":"525_CR40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012, 71: 314\u2013322.","journal-title":"Ann Neurol"},{"key":"525_CR41","first-page":"524","volume":"24","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Biotechnology 1975, 24: 524.","journal-title":"Biotechnology"},{"key":"525_CR42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/icb.1990.50","volume":"68","author":"JJ Tjandra","year":"1990","unstructured":"Tjandra JJ, Ramadi L, McKenzie IFC. Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 1990, 68: 367\u2013376.","journal-title":"Immunol Cell Biol"},{"key":"525_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WYK Hwang","year":"2005","unstructured":"Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36: 3\u201310.","journal-title":"Methods"},{"key":"525_CR44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2006.01.026","volume":"58","author":"LG Presta","year":"2006","unstructured":"Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006, 58: 640\u2013656.","journal-title":"Adv Drug Deliv Rev"},{"key":"525_CR45","first-page":"899","volume":"12","author":"LS Jespers","year":"1994","unstructured":"Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology 1994, 12: 899.","journal-title":"Biotechnology"},{"key":"525_CR46","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","volume":"262","author":"H Z\u00e9phir","year":"2015","unstructured":"Z\u00e9phir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 2015, 262: 2329\u20132335.","journal-title":"J Neurol"},{"key":"525_CR47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2013.240","volume":"28","author":"GTM Le","year":"2014","unstructured":"Le GTM, Herbi L, De RC, Nguyen-Khac F, Davi F, Grelier A, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia 2014, 28: 230\u2013233.","journal-title":"Leukemia"},{"key":"525_CR48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12: 554\u2013562.","journal-title":"Lancet Neurol"},{"key":"525_CR49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","volume":"23","author":"M Araki","year":"2013","unstructured":"Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013, 23: 827\u2013831.","journal-title":"Mod Rheumatol"},{"key":"525_CR50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","volume":"6","author":"MA Mealy","year":"2015","unstructured":"Mealy MA, Shin K, John G, Levy M. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol 2015, 6: 413\u2013418.","journal-title":"Clin Exp Neuroimmunol"},{"key":"525_CR51","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","volume":"20","author":"RP Taylor","year":"2008","unstructured":"Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008, 20: 444\u2013449.","journal-title":"Curr Opin Immunol"},{"key":"525_CR52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al. Intrathecal pathogenic anti\u2013aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009, 66: 617\u2013629.","journal-title":"Ann Neurol"},{"key":"525_CR53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2017.07.013","volume":"186","author":"R Hohlfeld","year":"2018","unstructured":"Hohlfeld R. B-cells as therapeutic targets in neuro-inflammatory diseases. Clin Immunol 2018, 186: 51\u201353.","journal-title":"Clin Immunol"},{"key":"525_CR54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","volume":"66","author":"SR Hinson","year":"2009","unstructured":"Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4\u2013expressing cells. Arch Neurol 2009, 66: 1164-1167.","journal-title":"Arch Neurol"},{"key":"525_CR55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","volume":"123","author":"J Ratelade","year":"2012","unstructured":"Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 2012, 123: 861\u2013872.","journal-title":"Acta Neuropathol"},{"key":"525_CR56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B Cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005, 62: 258-264.","journal-title":"Arch Neurol"},{"key":"525_CR57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.med.55.091902.104249","volume":"55","author":"W Rastetter","year":"2004","unstructured":"Rastetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004, 55: 477\u2013503.","journal-title":"Annu Rev Med"},{"key":"525_CR58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","volume":"4","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008, 4: 557\u2013567.","journal-title":"Nat Clin Pract Neurol"},{"key":"525_CR59","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","volume":"3","author":"J Graves","year":"2014","unstructured":"Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, et al. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord 2014, 3: 244\u2013252.","journal-title":"Mult Scler Relat Disord"},{"key":"525_CR60","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.24998","volume":"60","author":"E Wilk","year":"2009","unstructured":"Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009, 60: 3563\u20133571.","journal-title":"Arthritis Rheum"},{"key":"525_CR61","first-page":"710","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis. Optica 2013, 81: 710\u2013713.","journal-title":"Optica"},{"key":"525_CR62","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JCW Edwards","year":"2004","unstructured":"Edwards JCW, Szechinski J, Emery P, Shaw T. Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350: 2572\u20132581.","journal-title":"N Engl J Med"},{"key":"525_CR63","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Arnold DL, Fox RJ, Sarkar N, Smith CH. B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis. N Engl J Med 2008, 358: 676\u2013688.","journal-title":"N Engl J Med"},{"key":"525_CR64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/1744666X.4.5.573","volume":"4","author":"D Reske","year":"2008","unstructured":"Reske D, Haupt WF. Use of rituximab in multiple sclerosis: current progress and future perspectives. Expert Rev Clin Immunol 2008, 4: 573\u2013582.","journal-title":"Expert Rev Clin Immunol"},{"key":"525_CR65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/01676830903104611","volume":"28","author":"M Salvi","year":"2009","unstructured":"Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 2009, 28: 251\u2013255.","journal-title":"Orbit"},{"key":"525_CR66","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64: 1270\u20131272.","journal-title":"Neurology"},{"key":"525_CR67","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler J 2011, 17: 1225\u20131230.","journal-title":"Mult Scler J"},{"key":"525_CR68","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","volume":"22","author":"N Collongues","year":"2016","unstructured":"Collongues N, Brassat D, Maillart E, Labauge P, Ouallet J, Carra-Dalliere C, et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler J 2016, 22: 955\u2013959.","journal-title":"Mult Scler J"},{"key":"525_CR69","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013, 70: 1110\u20131117.","journal-title":"JAMA Neurol"},{"key":"525_CR70","doi-asserted-by":"crossref","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","volume":"13","author":"AB Memon","year":"2018","unstructured":"Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One 2018, 13: e0190425.","journal-title":"PLoS One"},{"key":"525_CR71","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017, 264: 2003\u20132009.","journal-title":"J Neurol"},{"key":"525_CR72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","volume":"174","author":"J Ciron","year":"2018","unstructured":"Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol 2018, 174: 255\u2013264.","journal-title":"Rev Neurol"},{"key":"525_CR73","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009, 10: 816\u2013824.","journal-title":"Lancet Oncol"},{"key":"525_CR74","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011, 68: 1156\u20131164.","journal-title":"Arch Neurol"},{"key":"525_CR75","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","volume":"7","author":"Y Tsutsumi","year":"2015","unstructured":"Tsutsumi Y. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015, 7: 2344.","journal-title":"World J Hepatol"},{"key":"525_CR76","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.14447","volume":"176","author":"JP Sharman","year":"2017","unstructured":"Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol 2017, 176: 412\u2013420.","journal-title":"Br J Haematol"},{"key":"525_CR77","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10616-011-9377-2","volume":"64","author":"Y Konno","year":"2012","unstructured":"Konno Y, Kobayashi Y, Takahashi K, Takahashi E, Sakae S, Wakitani M, et al. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology 2012, 64: 249\u2013265.","journal-title":"Cytotechnology"},{"key":"525_CR78","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","volume":"25","author":"MA Agius","year":"2017","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler 2017, 25: 235\u2013245.","journal-title":"Mult Scler"},{"key":"525_CR79","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","volume":"5","author":"TF Tedder","year":"2009","unstructured":"Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5: 572\u2013577.","journal-title":"Nat Rev Rheumatol"},{"key":"525_CR80","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","volume":"197","author":"E Schuh","year":"2016","unstructured":"Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, et al. Features of human CD3+ CD20+ T cells. J Immunol 2016, 197: 1111\u20131117.","journal-title":"J Immunol"},{"key":"525_CR81","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014, 193: 580\u2013586.","journal-title":"J Immunol"},{"key":"525_CR82","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","volume":"4","author":"O Hammer","year":"2012","unstructured":"Hammer O. CD19 as an attractive target for antibody-based therapy. mAbs 2012, 4: 571\u2013577.","journal-title":"mAbs"},{"key":"525_CR83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 2016, 18: 131.","journal-title":"Arthritis Res Ther"},{"key":"525_CR84","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 2019, 394: 1352\u20131363.","journal-title":"Lancet"},{"key":"525_CR85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00401-014-1313-z","volume":"128","author":"O St\u00fcve","year":"2014","unstructured":"St\u00fcve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, et al. CD19 as a molecular target in CNS autoimmunity. Acta Neuropathol 2014, 128: 177\u2013190.","journal-title":"Acta Neuropathol"},{"key":"525_CR86","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25: 1256\u20131264.","journal-title":"Nat Biotechnol"},{"key":"525_CR87","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458506070145","volume":"13","author":"GJD Hengstman","year":"2007","unstructured":"Hengstman GJD, Wesseling P, Frenken CWGM, Jongen PJH. Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult Scler J 2007, 13: 679\u2013682.","journal-title":"Mult Scler J"},{"key":"525_CR88","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133: 349\u2013361.","journal-title":"Brain"},{"key":"525_CR89","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","volume":"70","author":"H Zhang","year":"2011","unstructured":"Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011, 70: 943\u2013954.","journal-title":"Ann Neurol"},{"key":"525_CR90","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11: 785\u2013797.","journal-title":"Nat Immunol"},{"key":"525_CR91","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","volume":"25","author":"D Ricklin","year":"2007","unstructured":"Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007, 25: 1265\u20131275.","journal-title":"Nat Biotechnol"},{"key":"525_CR92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nsmb.3196","volume":"23","author":"MM Jore","year":"2016","unstructured":"Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, et al. Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol 2016, 23: 378\u2013386.","journal-title":"Nat Struct Mol Biol"},{"key":"525_CR93","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder. N Engl J Med 2019, 381: 614\u2013625.","journal-title":"N Engl J Med"},{"key":"525_CR94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","volume":"52","author":"T Tanaka","year":"2012","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012, 52: 199\u2013219.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"525_CR95","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011, 108: 3701\u20133706.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"525_CR96","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"A Uzawa","year":"2013","unstructured":"Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 2013, 421: 181\u2013183.","journal-title":"Clin Chim Acta"},{"key":"525_CR97","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","volume":"19","author":"H Wang","year":"2012","unstructured":"Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, et al. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 2012, 19: 304\u2013308.","journal-title":"Neuroimmunomodulation"},{"key":"525_CR98","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","volume":"70","author":"BC Kieseier","year":"2013","unstructured":"Kieseier BC, St\u00fcve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013, 70: 390.","journal-title":"JAMA Neurol"},{"key":"525_CR99","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14397595.2013.861333","volume":"26","author":"T Komai","year":"2016","unstructured":"Komai T, Shoda H, Yamaguchi K, Sakurai K, Shibuya M, Kubo K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Mod Rheumatol 2016, 26: 294\u2013296.","journal-title":"Mod Rheumatol"},{"key":"525_CR100","first-page":"104315","volume":"2018","author":"M Araki","year":"2018","unstructured":"Araki M. Blockade of IL-6 signaling in neuromyelitis optica. Neurochem Int 2018, 2018: 104315.","journal-title":"Neurochem Int"},{"key":"525_CR101","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"M Ringelstein","year":"2015","unstructured":"Ringelstein M, Ayzenberg I, Harmel J, Lauenstein A-S, Lensch E, St\u00f6gbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015, 72: 756.","journal-title":"JAMA Neurol"},{"key":"525_CR102","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schr\u00f6der A, Hellwig K, Chan A, Yamamura T, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013, 70: 394\u2013397.","journal-title":"JAMA Neurol"},{"key":"525_CR103","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/archneurol.2012.768","volume":"69","author":"P Qian","year":"2012","unstructured":"Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012, 69: 1482\u20131487.","journal-title":"Arch Neurol"},{"key":"525_CR104","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00586-012-2183-5","volume":"21","author":"S Ohtori","year":"2012","unstructured":"Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J 2012, 21: 2079\u20132084.","journal-title":"Eur Spine J"},{"key":"525_CR105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458515623862","volume":"22","author":"P Beauchemin","year":"2016","unstructured":"Beauchemin P, Carruthers R. MS arising during Tocilizumab therapy for rheumatoid arthritis. Mult Scler J 2016, 22: 254\u2013256.","journal-title":"Mult Scler J"},{"key":"525_CR106","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","volume":"75","author":"C Gabay","year":"2016","unstructured":"Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016, 75: 1806\u20131812.","journal-title":"Ann Rheum Dis"},{"key":"525_CR107","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10067-011-1827-x","volume":"30","author":"T Gout","year":"2011","unstructured":"Gout T, \u00d6st\u00f6r AJK, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011, 30: 1471\u20131474.","journal-title":"Clin Rheumatol"},{"key":"525_CR108","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0030-1255931","volume":"43","author":"T Iwasa","year":"2011","unstructured":"Iwasa T, Nakamura K, Ogino H, Itaba S, Akiho H, Okamoto R, et al. Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis. Endoscopy 2011, 43: 70\u201372.","journal-title":"Endoscopy"},{"key":"525_CR109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","volume":"27","author":"F Paul","year":"2018","unstructured":"Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 2018, 27: 265\u2013271.","journal-title":"Expert Opin Investig Drugs"},{"key":"525_CR110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","volume":"10","author":"H Kaplon","year":"2018","unstructured":"Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs 2018, 10: 183\u2013203.","journal-title":"mAbs"},{"key":"525_CR111","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019, 381: 2114\u20132124.","journal-title":"N Engl J Med"},{"key":"525_CR112","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7: 335\u2013345.","journal-title":"Angiogenesis"},{"key":"525_CR113","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","volume":"83","author":"F Shimizu","year":"2012","unstructured":"Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, et al. Sera from neuromyelitis optica patients disrupt the blood\u2013brain barrier. J Neurol Neurosurg Psychiatry 2012, 83: 288\u2013297.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"525_CR114","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","volume":"181","author":"T Vincent","year":"2008","unstructured":"Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, et al. Functional consequences of neuromyelitis optica-igg astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008, 181: 5730\u20135737.","journal-title":"J Immunol"},{"key":"525_CR115","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.0808698106","volume":"106","author":"AT Argaw","year":"2009","unstructured":"Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A 2009, 106: 1977\u20131982.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"525_CR116","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1172\/JCI60842","volume":"122","author":"AT Argaw","year":"2012","unstructured":"Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012, 122: 2454\u20132468.","journal-title":"J Clin Invest"},{"key":"525_CR117","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009, 66: 630\u2013643.","journal-title":"Ann Neurol"},{"key":"525_CR118","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","volume":"125","author":"PW Phuan","year":"2013","unstructured":"Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol 2013, 125: 829\u2013840.","journal-title":"Acta Neuropathol"},{"key":"525_CR119","first-page":"875","volume":"78","author":"B Bourre","year":"2012","unstructured":"Bourre B, Marignier R, Zephir H, Papeix C, Brassat D, Castelnovo G, et al. Neuromyelitis optica and pregnancy 2012, 78: 875\u2013879.","journal-title":"Neuromyelitis optica and pregnancy"},{"key":"525_CR120","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","volume":"78","author":"W Kim","year":"2012","unstructured":"Kim W, Kim S-H, Nakashima I, Takai Y, Fujihara K, Leite MI, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 2012, 78: 1264\u20131267.","journal-title":"Neurology"},{"key":"525_CR121","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2004.00214.x","volume":"72","author":"E Kimby","year":"2004","unstructured":"Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004, 72: 292\u2013295.","journal-title":"Eur J Haematol"},{"key":"525_CR122","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10067-012-2156-4","volume":"32","author":"M Ojeda-Uribe","year":"2013","unstructured":"Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013, 32: 695\u2013700.","journal-title":"Clin Rheumatol"},{"key":"525_CR123","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaad.2009.05.015","volume":"63","author":"P Ponte","year":"2010","unstructured":"Ponte P, Lopes MJP. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 2010, 63: 355\u2013356.","journal-title":"J Am Acad Dermatol"},{"key":"525_CR124","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1177\/1352458513498125","volume":"19","author":"M Ringelstein","year":"2013","unstructured":"Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler J 2013, 19: 1544\u20131547.","journal-title":"Mult Scler J"},{"key":"525_CR125","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","volume":"21","author":"N Simister","year":"2003","unstructured":"Simister N. Placental transport of immunoglobulin G. Vaccine 2003, 21: 3365\u20133369.","journal-title":"Vaccine"},{"key":"525_CR126","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm 2018, 5: e453.","journal-title":"Neurol Neuroimmunol. Neuroinflamm"},{"key":"525_CR127","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.4049\/jimmunol.1600135","volume":"197","author":"K Shi","year":"2016","unstructured":"Shi K, Wang Z, Liu Y, Gong Y, Fu Y, Li S, et al. CFHR1-modified neural stem cells ameliorated brain injury in a mouse model of neuromyelitis optica spectrum disorders. J Immunol 2016, 197: 3471\u20133480.","journal-title":"J Immunol"},{"key":"525_CR128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbi.2017.04.023","volume":"65","author":"Z Wang","year":"2017","unstructured":"Wang Z, Guo W, Liu Y, Gong Y, Ding X, Shi K, et al. Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes. Brain Behav Immun 2017, 65: 173\u2013182.","journal-title":"Brain Behav Immun"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-020-00525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-020-00525-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-020-00525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:28:43Z","timestamp":1623439723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-020-00525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":128,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1007\/s12264-020-00525-3","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"8 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}